$17.11
5.26%
Nasdaq, Sep 18, 04:26 pm EDT. Closed.
ISIN
US26817R1086
Symbol
DYN

Dyne Therapeutics Inc Target price 2026 - Analyst rating & recommendation

Dyne Therapeutics Inc Classifications & Recommendation

Buy
90%
Hold
10%

Dyne Therapeutics Inc Price Target

Target Price $40.80
Price $17.11
Potential
Number of Estimates 15
15 Analysts have issued a price target Dyne Therapeutics Inc 2027 . The average Dyne Therapeutics Inc target price is $40.80. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 21 analysts: 19 Analysts recommend Dyne Therapeutics Inc to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Dyne Therapeutics Inc stock has an average upside potential 2027 of . Most analysts recommend the Dyne Therapeutics Inc stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Earnings Per Share $ -3.47 -3.63
2.97% 4.61%
P/E negative

18 Analysts have issued a Dyne Therapeutics Inc forecast for earnings per share. The average Dyne Therapeutics Inc EPS is

$-3.63
unlock
. This is
15.97% lower
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$-3.32 6.07%
unlock
, the lowest is
$-3.86 23.32%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $-3.47 2.97%
2026
$-3.63 4.61%
unlock
2027
$-3.49 3.86%
unlock
2028
$-2.86 18.05%
unlock
2029
$-0.22 92.31%
unlock
2030
$2.13 1,068.18%
unlock
2031
$4.30 101.88%
unlock
2032
$6.61 53.72%
unlock
2033
$7.61 15.13%
unlock

P/E ratio

Current -5.47 50.48%
2026
-4.71 13.84%
unlock
2027
-4.91 4.25%
unlock
2028
-5.98 21.79%
unlock
2029
-77.00 1,187.63%
unlock
2030
8.04 110.44%
unlock
2031
3.98 50.50%
unlock
2032
2.59 34.92%
unlock
2033
2.25 13.13%
unlock

Current Dyne Therapeutics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
JP Morgan
Locked
Locked
Locked Sep 09 2026
Baird
Locked
Locked
Locked Sep 09 2026
RBC Capital
Locked
Locked
Locked Sep 09 2026
Morgan Stanley
Locked
Locked
Locked Sep 09 2026
Morgan Stanley
Locked
Locked
Locked Jul 31 2026
RBC Capital
Locked
Locked
Locked Jul 30 2026
Cantor Fitzgerald
Locked
Locked
Locked Jul 23 2026
Analyst Rating Date
Locked
JP Morgan:
Locked
Locked
Sep 09 2026
Locked
Baird:
Locked
Locked
Sep 09 2026
Locked
RBC Capital:
Locked
Locked
Sep 09 2026
Locked
Morgan Stanley:
Locked
Locked
Sep 09 2026
Locked
Morgan Stanley:
Locked
Locked
Jul 31 2026
Locked
RBC Capital:
Locked
Locked
Jul 30 2026
Locked
Cantor Fitzgerald:
Locked
Locked
Jul 23 2026

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today